Literature DB >> 10961574

Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions.

A H Schmaier1.   

Abstract

Recent studies indicate that assembly of high molecular weight kininogen on its multiprotein receptor allows for prekallikrein activation. On endothelial cells, factor XII activation is secondary to prekallikrein activation and amplifies it. The immediate consequence of plasma prekallikrein activation is the cleavage of high molecular weight kininogen (HK) with liberation of bradykinin. Cleaved high molecular weight kininogen is antiangiogenic. Bradykinin stimulates tPA liberation and nitric oxide formation. In addition, formed plasma kallikrein promotes single-chain urokinase activation and subsequent plasminogen activation. Kininogens and their breakdown products also are antithrombins. The angiotensin converting enzyme breakdown product of bradykinin prevents canine coronary thrombosis. The author presents a new hypothesis for physiologic assembly and activation of the plasma kallikrein/kinin system and discusses its influence on vascular biology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961574     DOI: 10.1097/00062752-200009000-00001

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  6 in total

1.  Plasmin alters the activity and quaternary structure of human plasma carboxypeptidase N.

Authors:  Mercy O Quagraine; Fulong Tan; Hironori Tamei; Ervin G Erdös; Randal A Skidgel
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

Review 2.  Human plasma kallikrein-kinin system: physiological and biochemical parameters.

Authors:  J W Bryant; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-07

3.  Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.

Authors:  Coen Maas; José W P Govers-Riemslag; Barend Bouma; Bettina Schiks; Bouke P C Hazenberg; Henk M Lokhorst; Per Hammarström; Hugo ten Cate; Philip G de Groot; Bonno N Bouma; Martijn F B G Gebbink
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

4.  An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema.

Authors:  Jingxuan Liu; June Qin; Anna Borodovsky; Timothy Racie; Adam Castoreno; Mark Schlegel; Martin A Maier; Tracy Zimmerman; Kevin Fitzgerald; James Butler; Akin Akinc
Journal:  RNA       Date:  2018-11-21       Impact factor: 4.942

5.  Kininogen-Nitric Oxide Signaling at Nearby Nonexcited Acupoints after Long-Term Stimulation.

Authors:  Ting Wang; Geng Zhu; Liyue Qin; Qian Wang; Chen She; Dongsheng Xu; Weiwei Hu; Kenghuo Luo; Ying Lei; Yanling Gong; Arijit Ghosh; Dongni Ma; Chun-Lei Ding; Bu-Yi Wang; Yang Guo; Shou-Shan Ma; Michihiro Hattori; Yutaka Takagi; Katsutoshi Ara; Kazuhiko Higuchi; Xingwang Li; Lin He; Wanzhu Bai; Koichi Ishida; Sheng-Tian Li
Journal:  JID Innov       Date:  2021-06-24

6.  Evaluation of anti-inflammatory activity and molecular docking study of new aza-bicyclic isoxazoline acylhydrazone derivatives.

Authors:  Fernanda Virginia Barreto Mota; Marlene Saraiva de Araújo Neta; Eryvelton de Souza Franco; Isla Vanessa Gomes Alves Bastos; Larissa Cardoso Correia da Araújo; Sandra Cabral da Silva; Tatiane Bezerra de Oliveira; Eduarda Karynne Souza; Valderes Moraes de Almeida; Rafael Matos Ximenes; Maria Bernadete de Sousa Maia; Francisco Jaime Bezerra Mendonça Junior; Pascal Marchand; Antônio Rodolfo de Faria; Teresinha Gonçalves da Silva
Journal:  Medchemcomm       Date:  2019-09-12       Impact factor: 3.597

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.